Belgium· BE-AMP-SAM307307-00
Increlex 10 mg/ml
A mecasermin product containing mecasermin, registered in Belgium by Esteve Pharmaceuticals. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Mecasermin is registered in 12 of 19 countries.
Countries holding a registration under ATC H01AC03 (mecasermin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Mecasermin · ATC H01AC03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Mecasermin
- Manufacturer
- Esteve Pharmaceuticals
- Country
- Belgium (BE)
- ATC code
- H01AC03
- ATC class
- Mecasermin
- Defined daily dose
- 2 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0789354
- be_apb2441368
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
25 interactions on record for mecasermin.
Graded by severity as the source publishes them — 25 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mecasermin · interactions on record
25 records
- 25 moderate
Most severe, free to view
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Insulin aspartA10AB05moderate
- Insulin glulisineA10AB06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mecasermin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINCRELEXEsteve Pharmaceuticals S.A., Barcelona
- SpainINCRELEX 10 mg/ml SOLUCION INYECTABLEEsteve Pharmaceuticals S.A.
- IcelandIncrelexEsteve Pharmaceuticals S.A.
- NorwayIncrelexEsteve Pharmaceuticals S.A
- PolandIncrelexIpsen Pharma
- SwedenINCRELEX 10 mg/ml Injektionsvätska, lösningEsteve Pharmaceuticals S.A.
- United StatesGUNA-IGFGuna spa
- FinlandIncrelexEsteve Pharmaceuticals, S.A
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Increlex
- Liechtenstein · Increlex
- Norway · Increlex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/89233457-d55a-4fad-9f82-7bda5a1a45f1 GET /v1/drugs/89233457-d55a-4fad-9f82-7bda5a1a45f1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Increlex 10 mg/ml",
"name_fr": "Increlex 10 mg/ml",
"name_nl": "Increlex 10 mg/ml",
"amp_code": "SAM307307-00",
"strengths": [
"10.0000",
"10.0000",
"9.0000"
],
"pack_count": 1,
"substances": [
"Mecasermin",
"Benzyl Alcohol",
"Sodium Acetate",
"Sodium Chloride",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Mecasermin",
"authorisation_numbers": [
"EU/1/07/402/001"
]
}See everything about mecasermin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.